Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Change in tumor size on MRI after a 6-week biologic window for patients on standard treatment

From: A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

Response N Mean shrinkage (cm) Std. dev Minimum (cm) Maximum (cm)
No 6 − 0.13 0.45 − 1.0 0.3
Yes 5 2.58 1.88 0.2 4.9